Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How VC-Backed Companies Can Get More Out of Their Boards

This article was originally published in Start Up

Executive Summary

VC-backed start-ups may need to think and act differently, perhaps more judiciously, about effective governance than more established firms. The stakes for start-ups are higher and the environment for failure is less forgiving than for established enterprises. In addition to their oversight role, directors at start-ups should be considered strategic assets. Developing a relation-based model built on a board/CEO partnership can increase the odds for success.

You may also be interested in...

What Entrepreneurs Want, Get, and Don't Get from VCs

What makes a health care VC stand out in the minds of entrepreneurs? According to a first-of-its-kind survey by Windhover, PricewaterhouseCoopers, Wilson Sonsini, and Applied Information Networks, the answer is value-added services. Entrepreneurs prize VCs who assist them, pre-financing, with constructive feedback and sharing of due diligence results. VCs do pretty well here. But they do less well on the more important post-financing criteria: helping their portfolio companies secure additional financing and recruit customers, partners, and employees.

Good Boards, Bad Boards and Why They Matter

What distinguishes an effective board of directors of an early-stage biotech company? The ability to walk a very fine line between constructive engagement and outright control. Good boards: small, focused, with an independent, mentoring chairman.

Re-Starting Heartport

Heartport was the darling of investors when it burst on the scene in 1996 with a new minimally-invasive cardiac surgery technology. The company's stratospheric IPO valuation quickly deflated as cardiac surgeons, proving more cautious than investors, have been slow in adopting Heartport's technique. Armed with new management and a new strategy, Heartport is regrouping, still convinced, in the face of major competitors using a different approach, that its technology represents the future of minimally-invasive cardiac surgery.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts